Abstract:Triple-negative breast cancer (TNBC) patients have a poor prognosis and few treatment options. Mouse models of TNBC are important for development of new targeted therapies, but few TNBC mouse models exist. Here, we developed a novel TNBC murine model by mimicking two common TNBC mutations with high co-occurrence: amplification of the oncogene MYC and deletion of the tumor suppressor PTEN. This Myc;Ptenfl murine model develops TN mammary tumors that display histological and molecular features commonly found in human TNBC. We performed deep omic analyses on Myc;Ptenfl tumors including machine learning for morphologic features, bulk and single-cell RNA-sequencing, multiplex immunohistochemistry and single-cell phenotyping. Through comparison with human TNBC, we demonstrated that this new genetic mouse model develops mammary tumors with differential survival that closely resemble the inter- and intra-tumoral and microenvironmental heterogeneity of human TNBC; providing a unique pre-clinical tool for assessing the spectrum of patient TNBC biology and drug response. Statement of significance The development of cancer models that mimic triple-negative breast cancer (TNBC) microenvironment complexities is critical to develop effective drugs and enhance disease understanding. This study addresses a critical need in the field by identifying a murine model that faithfully mimics human TNBC heterogeneity and establishing a foundation for translating preclinical findings into effective human clinical trials. ### Competing Interest Statement Rosalie C. Sears: Consultant: Novartis Pharmaceutical, Larkspur Biosciences. Scientific Advisory Board: RAPPTA Therapeutics. Sponsored Research Support: Cardiff Oncology, Astra Zeneca Partner of Choice grant award. Gordon Mills: SAB/Consultant: Amphista, Astex, AstraZeneca, BlueDot, Chrysallis Biotechnology, Ellipses Pharma, ImmunoMET, Infinity, Ionis, Leapfrog Bio, Lilly, Medacorp, Nanostring, Nuvectis, PDX Pharmaceuticals, Qureator, Roche, Signalchem Lifesciences, Tarveda, Turbine, Zentalis Pharmaceuticals. Stock/Options/Financial: Bluedot, Catena Pharmaceuticals, ImmunoMet, Nuvectis, SignalChem, Tarveda, Turbine, Licensed Technology, HRD assay to Myriad Genetics, DSP patents with Nanostring. Sponsored research: AstraZeneca, Nanostring Center of Excellence, Ionis (Provision of tool compounds. Lisa M. Coussens reports consulting services for Cell Signaling Technologies, AbbVie, the Susan G Komen Foundation, and Shasqi, received reagent and/or research support from Cell Signaling Technologies, Syndax Pharmaceuticals, ZelBio Inc., Hibercell Inc., and Acerta Pharma, and has participated in advisory boards for Pharmacyclics, Syndax, Carisma, Verseau, CytomX, Kineta, Hibercell, Cell Signaling Technologies, Alkermes, Zymeworks, Genenta Sciences, Pio Therapeutics Pty Ltd., PDX Pharmaceuticals, the AstraZeneca Partner of Choice Network, the Lustgarten Foundation, and the NIH/NCI-Frederick National Laboratory Advisory Committee. All the others authors declare no competing interests.

Supplementary Table S3 from Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models

Supplementary Table S4 from Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models

Supplementary Table S1 from Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models

Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models.

Supplementary Methods and Table from Frequent <i>Met</i> Oncogene Amplification in a <i>Brca1/Trp53</i> Mouse Model of Mammary Tumorigenesis

Patient-derived Human Tumour Tissue Xenografts in Immunodeficient Mice: a Systematic Review

Supplementary Figure 6 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Supplementary Data from Genetically Defined Syngeneic Mouse Models of Ovarian Cancer As Tools for the Discovery of Combination Immunotherapy

Supplementary Figure S2 from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

Supplementary Figure 4 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Supplementary Figure 9 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Abstract #LB-65: Test of Cytotoxic and Targeted Anticancer Drugs Using Human Primary Non-Small Cell Lung Cancer Xenograft Models

Supplementary Figure 5 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Supplementary Table 1 from Eradication of Solid Human Breast Tumors in Nude Mice with an Intravenously Injected Light-Emitting Oncolytic Vaccinia Virus

Abstract 9: Histological characterization of two genetically engineered mouse models of non-small cell lung cancer

Supplementary Tables 1 Through 8 from Immune Escape in Breast Cancer During in Situ to Invasive Carcinoma Transition

Supplementary Figures 1-3 from OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models

A Novel Mouse Model that Recapitulates the Heterogeneity of Human Triple Negative Breast Cancer

Figure S1-S14, Table S1-S2 & S4-S6 from Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib Through a Genome-Targeted Approach

Assessing Longitudinal Treatment Efficacies and Alterations in Molecular Markers Associated with Glutamatergic Signaling and Immune Checkpoint Inhibitors in a Spontaneous Melanoma Mouse Model

Data from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice